Pembrolizumab/Entinostat Active in Melanoma Patients Refractory to Checkpoint Inhibitors


“Combining the PD-1 inhibitor pembrolizumab (Keytruda) with the HDAC inhibitor entinostat demonstrated promising clinical activity and acceptable safety in patients with melanoma who were refractory to immune checkpoint inhibitors.

“In the ongoing phase II ENCORE 601 trial, the PD-1/HDAC combination induced a response in 4 of 13 patients (31%; 95% CI, 9-61). The responses comprised 3 confirmed responses and 1 unconfirmed response, according to the study findings, which were presented in a poster at the 2017 ASCO Annual Meeting. An additional 4 patients achieved stable disease.”

Go to full article.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to use our ASK Cancer Commons service.